Latest Ratios: P/E Ratio 5.7x · EV/EBITDA 5.8x · ROE 22.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $53M | $74M | $37M | $44M | $79M | $46M | $49M | $39M | $31M | $17M | $32M |
| Enterprise Value | $53M | $74M | $38M | $45M | $80M | $48M | $49M | $41M | $35M | $20M | $32M |
| P/E Ratio → | 5.72 | 8.02 | 69.91 | 158.42 | 15.27 | 9.56 | — | — | — | — | 24.98 |
| P/S Ratio | 105.39 | 146.07 | 17.48 | 1.29 | — | — | — | — | — | — | 17.18 |
| P/B Ratio | 1.14 | 1.60 | 1.04 | 1.31 | 2.71 | 2.15 | 3.14 | 3.08 | 2.35 | 1.25 | 2.05 |
| P/FCF | — | — | 1449.43 | — | — | — | — | 12.65 | — | — | 19.80 |
| P/OCF | — | — | 1449.43 | — | — | — | — | 12.65 | — | — | 19.80 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 146.29 | 17.82 | 1.31 | — | — | — | — | — | — | 17.52 |
| EV / EBITDA | 5.79 | 8.02 | 18.45 | 54.05 | 13.07 | 8.71 | — | — | — | — | 21.91 |
| EV / EBIT | 5.79 | 8.02 | 61.10 | 137.12 | 15.21 | 10.04 | — | — | — | — | 21.91 |
| EV / FCF | — | — | 1477.84 | — | — | — | — | 13.08 | — | — | 20.19 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 37.5% | 37.5% | 100.0% | 99.5% | 407.6% | 138.3% | 124.5% | 419.3% | 129.2% | 119.8% | 84.9% |
| Operating Margin | 1824.7% | 1824.7% | 29.2% | 1.0% | -1485.9% | -181.6% | 61.7% | 431.1% | 119.4% | 112.9% | 80.0% |
| Net Profit Margin | 1821.5% | 1821.5% | 25.2% | 0.8% | -1465.4% | -181.6% | 60.8% | 431.1% | 96.4% | 122.6% | 79.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 22.5% | 22.5% | 1.5% | 0.9% | 20.7% | 25.8% | -12.0% | -3.8% | -6.6% | -8.5% | 9.8% |
| ROA | 22.2% | 22.2% | 1.5% | 0.9% | 18.7% | 22.9% | -11.1% | -3.1% | -4.8% | -6.2% | 7.0% |
| ROIC | 16.7% | 16.7% | 1.3% | 0.8% | 14.7% | 18.4% | -8.8% | -2.4% | -4.8% | -5.2% | 6.9% |
| ROCE | 22.3% | 22.3% | 1.7% | 1.0% | 19.3% | 23.7% | -11.6% | -3.1% | -6.0% | -5.7% | 7.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.02 | 0.04 | 0.14 | 0.01 | 0.11 | 0.34 | 0.32 | 0.18 |
| Debt / EBITDA | 0.01 | 0.01 | 0.35 | 0.90 | 0.20 | 0.55 | — | — | — | — | 1.91 |
| Net Debt / Equity | — | 0.00 | 0.02 | 0.02 | 0.04 | 0.11 | -0.03 | 0.11 | 0.34 | 0.24 | 0.04 |
| Net Debt / EBITDA | 0.01 | 0.01 | 0.35 | 0.90 | 0.20 | 0.42 | — | — | — | — | 0.42 |
| Debt / FCF | — | — | 28.41 | — | — | — | — | 0.43 | — | — | 0.39 |
| Interest Coverage | 575.44 | 575.44 | 7.30 | 6.72 | 72.47 | 243.19 | -204.98 | -3.45 | -10.05 | -41.21 | 39.31 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | — | 0.17 | 0.25 | 0.61 | 0.95 | — | 0.42 | 0.51 | 0.60 | 335.00 |
| Quick Ratio | — | — | 0.17 | 0.25 | 0.61 | 0.95 | — | 0.42 | 0.51 | 0.60 | 335.00 |
| Cash Ratio | — | — | — | — | — | 0.88 | 0.87 | — | — | 14.52 | 279.34 |
| Asset Turnover | — | 0.01 | 0.06 | 0.99 | -0.01 | -0.10 | -0.17 | -0.01 | -0.05 | -0.05 | 0.09 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 1.66 | 0.15 | -17.80 | -4.28 | -3.81 | -103.91 | -13.40 | -16.33 | 9.12 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | 0.7% | 0.4% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | 7.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 17.5% | 12.5% | 1.4% | 0.6% | 6.6% | 10.5% | — | — | — | — | 4.0% |
| FCF Yield | — | — | 0.1% | — | — | — | — | 7.9% | — | — | 5.1% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 1.4% | 1.4% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 2.1% | 1.7% |
| Shares Outstanding | — | $5M | $5M | $5M | $9M | $4M | $4M | $4M | $4M | $4M | $4M |
Investment Portfolio Market Sensitivity
As reported in recent financial filings, Daxor trades at a P/S ratio of 100.32, a figure that appears fundamentally detached from the company's contracting medical revenue and suggests that market participants are pricing the equity based on its investment portfolio rather than its core diagnostic business.
The P/E ratio of 5.45 is heavily influenced by non-recurring investment gains, which obscures the lack of sustainable earnings from the BVA-100 platform. Investors should monitor whether the market continues to value the company as a closed-end fund, as this valuation methodology fails to account for the high cash burn inherent in the medical device segment.
Based on historical data, Daxor's ROIC has shown extreme volatility, reaching 17.5% in 2025Q4, yet this metric is primarily a reflection of market-driven investment returns rather than the efficient deployment of capital into the company's medical instrumentation and diagnostic kit manufacturing operations.
The inconsistency in ROIC, which has frequently dipped into negative territory, indicates that the company is not compounding value through its core business activities. This suggests that the firm's ability to generate returns is structurally dependent on external market conditions rather than internal operational excellence or competitive advantage.
According to recent financial statements, Daxor's asset turnover remains near zero, reflecting the minimal contribution of medical device sales to the total asset base and highlighting the company's ongoing struggle to achieve meaningful commercial scale for its blood volume analysis technology in the hospital market.
The lack of consistent DSO and CCC data suggests that the company's sales cycle is either highly irregular or not yet optimized for a standard commercial model. This inefficiency warrants further investigation into whether the current placement strategy for the BVA-100 is effectively converting into recurring kit revenue.
As indicated by the company's reported figures, Daxor maintains a debt-to-equity ratio of 0.00, providing a fortress-like balance sheet that allows the firm to sustain its medical research and development efforts without the immediate pressure of debt service obligations or restrictive financial covenants.
While the absence of debt is a significant strength, it also reflects a conservative capital structure that may be under-utilizing the potential for growth-oriented financing. Investors should monitor whether this lack of leverage continues to be a strategic choice or a limitation imposed by the company's inability to secure traditional credit.
The most commonly misapplied ratio for Daxor is the net margin, which, as reported in recent filings, reached 72.4% in 2025Q4, creating a false impression of operational profitability that ignores the reality of the company's underlying medical device business and its reliance on investment portfolio gains.
Analysts should instead focus on the medical segment's standalone gross margin and cash burn rate to assess the true viability of the BVA-100. Using net margin as a proxy for performance in this specific business model obscures the fundamental disconnect between the company's investment activities and its commercial operations.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DXR stock.
Daxor Corporation's current P/E ratio is 5.7x. The historical average is 30.9x. This places it at the 9th percentile of its historical range.
Daxor Corporation's current EV/EBITDA is 5.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 22.3x.
Daxor Corporation's return on equity (ROE) is 22.5%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 0.7%.
Based on historical data, Daxor Corporation is trading at a P/E of 5.7x. This is at the 9th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Daxor Corporation has 37.5% gross margin and 1824.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Daxor Corporation's Debt/EBITDA ratio is 0.0x, indicating low leverage. A ratio below 2x is generally considered financially healthy.